WORK Medical Technology Group LTD Class A Ordinary Shares (WOK)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor in the Graham and Buffett tradition, so I begin with business quality and a margin of safety. WORK Medical sells disposable medical devices—masks, airways, anesthesia kits—in China and abroad. That is a real business with recurring consumable demand, but the numbers provided do not show a durable franchise. At the 2026-10-13 close of $1.39, market capitalization is only $1.5 million. FairStock’s P/E is -0.01, P/B is 0.00, ROE is -19.23%, and ROCE is -6.73%. Those are not the marks of a compounding machine. The Piotroski F-Score is 1/9, and the Altman Z-Score is 0.25, which point to acute financial weakness and distress risk. Debt-to-equity of 0.20 is not alarming by itself, but it means little when profitability is negative. There is no revenue growth or profit growth data provided, and the Lynch category is none because there are only zero years of filed results; I cannot assess a multi-year record. The 52-week range of $0.08 to $836.00 tells me the shares have been extraordinarily volatile, and beta of 1.75 confirms that. I see no reliable moat: medical consumables can be commoditized, and without sustained profits or returns above cost of capital, scale does not help. Valuation cannot be called cheap merely because the price is low. A negative P/E and no book value signal make the price dependent on a turnaround or speculation, not on demonstrated earning power. I would need several years of clean filings, positive free cash flow, and improving returns before this could interest a disciplined value investor.

In plain English: WORK Medical Technology Group makes and sells medical supplies like masks, airways and anesthesia kits in China and abroad. The business looks weak: it is losing money, has poor returns on capital, and very little financial history to judge. At $1.39, the price does not look cheap against those numbers; it looks speculative and unsupported by profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer